Vaxxinity Inc (VAXX)

Currency in USD
0.0150
-0.0150(-99.99%)
Closed·
VAXX Scorecard
Full Analysis
Stock generally trades with high price volatility
Unusual trading volume
Earnings results expected in 0 days
VAXX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.01500.0150
52 wk Range
0.00010.0700
Key Statistics
Prev. Close
-
Open
0.015
Day's Range
0.015-0.015
52 wk Range
0.0001-0.07
Volume
156.6K
Average Volume (3m)
17.69K
1-Year Change
650%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VAXX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Vaxxinity Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Vaxxinity Inc Company Profile

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer’s disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Compare VAXX to Peers and Sector

Metrics to compare
VAXX
Peers
Sector
Relationship
P/E Ratio
0.0x−4.1x−0.7x
PEG Ratio
0.000.030.00
Price/Book
0.0x1.9x2.6x
Price / LTM Sales
0.0x75.8x3.4x
Upside (Analyst Target)
0.0%104.0%37.3%
Fair Value Upside
Unlock4.8%5.2%Unlock

Earnings

Latest Release
Aug 29, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

VAXX Income Statement

People Also Watch

380.13
AVAV
+0.42%
182.54
CIEN
+1.95%
0.289
VIVK
-0.69%
72.99
IONS
+3.01%
1.5700
ZNB
-0.63%

FAQ

What Stock Exchange Does Vaxxinity Trade On?

Vaxxinity is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Vaxxinity?

The stock symbol for Vaxxinity is "VAXX."

What Is the Vaxxinity Market Cap?

As of today, Vaxxinity market cap is 126.00.

What Is Vaxxinity's Earnings Per Share (TTM)?

The Vaxxinity EPS (TTM) is -0.45.

When Is the Next Vaxxinity Earnings Date?

Vaxxinity will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is VAXX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Vaxxinity Stock Split?

Vaxxinity has split 0 times.

How Many Employees Does Vaxxinity Have?

Vaxxinity has 61 employees.

What is the current trading status of Vaxxinity (VAXX)?

As of 28 Oct 2025, Vaxxinity (VAXX) is trading at a price of 0.0150, with a previous close of 0.00. The stock has fluctuated within a day range of 0.0150 to 0.0150, while its 52-week range spans from 0.0001 to 0.0700.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.